IGFBPL1 anticorps (AA 201-278) (FITC)

N° du produit ABIN1710541

Détail du produit anti-IGFBPL1 anticorps (FITC)

Antigène: IGFBPL1 (Insulin-Like Growth Factor Binding Protein-Like 1 (IGFBPL1))

Épitope: AA 201-278

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp IGFBPL1 est conjugé à/à la FITC

Application: Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Homologie: Human,Mouse,Rat,Dog,Cow,Sheep,Pig,Horse

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human IGFBPL1

Isotype: IgG

Information d'application

Indications d'application: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur IGFBPL1

Antigène: IGFBPL1 (Insulin-Like Growth Factor Binding Protein-Like 1 (IGFBPL1))

Autre désignation: Igfbpl1 (IGFBPL1 Produits)

Synonymes: anticorps IGFBP-RP4, anticorps IGFBPRP4, anticorps bA113O24.1, anticorps 2810011G06Rik, anticorps 2810453O06Rik, anticorps IGFBPL, anticorps insulin like growth factor binding protein like 1, anticorps insulin-like growth factor binding protein-like 1, anticorps IGFBPL1, anticorps Igfbpl1

Sujet:

Synonyms: bA113O24.1, IGFBP-related protein 10, IGFBP-RP4, IGFBPRP4, insulin-like growth factor binding protein related protein 4, insulin-like growth factor-binding protein-like 1, IBPL1_HUMAN, insulin-like growth factor-binding-related protein 4.

Background: IGFBPL1 is a secreted IGF (Insulin-like growth factor) binding protein that is known to contain an Ig-like C2-type (immunoglobulin-like) domain, an IGFBP N-terminal domain and a Kazal-like domain. IGF-binding proteins characteristically act to extend the half-life of IGFs and may influence the growth promoting effects of the IGFs. The interaction of IGFBPs with IGFs can affect cell surface receptors, specifically, IGFBPs may enhance or decrease a cells insulin sensitivity. IGFBPL1 has been found to be down-regulated in multiple tumors and thus may be a likely tumor suppressor candidate. Highly expressed in both brain and testis, IGFBPL1 is found at lower levels in the prostate, bladder and lung.